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Genetic understanding in Parkinson’s disease (PD)
has followed a path of hard won evolution occasion-
ally punctuated by revolution. While it was suggested
early on by both Leroux and Gowers that heredity had
a role to play in PD, this was a view that wasn’t widely
enough held to even be unpopular. The dogma was
that the disease was one of environmental provenance
and while the evidence for this is still rather scarce,
this view pervades in the minds of patients, clinicians,
and scientists. Conversely the evidence linking genet-
ics to PD is both overwhelming and growing. Here
we describe the growth of genetics in PD from back-
water to driving force, and the structure and shape of
its future.
The localization and identification of -synuclein
mutations as a cause of PD in the mid 1990’s was
perhaps the first concrete and revolutionary find-
ing in PD genetics [1]. This came about as a result
of the intuition and hard work of a clinical team
from New Jersey, followed by the linkage and posi-
tional cloning efforts of a genetic team at NIH,
orchestrated by the then director of NINDS, Zach
Hall. This effort (described by Bob Nussbaum in
another article in this issue) was an extraordinary
success.
The discovery of -synuclein mutations as a rare
cause of PD was an invigorating and welcome pro-
gression for myriad reasons. Most prominently, it
gave us the mutation as a tool with which to attempt to
understand the disease process. Perhaps more impor-
tantly, at least in the short term, it provided empirical
evidence that there was a genetic basis for rare forms
of the disease and because -synuclein was a major
component of all Lewy bodies, that these findings
were directly relevant to all cases of PD. This in
fact, prompted one of us to say, tongue in cheek “If
you’re not working on synuclein, you’re not working
on Parkinson’s disease”.
A BRAVE NEW WORLD
With this finding not only did the scientists pur-
suing a functional understanding of PD have a new
tool but we as geneticists had a new ‘in’. Many of
us had previously worked in Alzheimer’s or known
monogenic disorders, but now there was a good ratio-
nale for concentrating more genetic efforts in PD.
This wasn’t based on a new belief that PD was a
genetic disease (being geneticists, we thought every-
thing was genetic anyway) but because the finding of
-synuclein mutations meant that the phrase “Parkin-
son’s is not a genetic disease” would be less evident
in the grant reviews we received from then on
(although sadly not entirely absent) and that there
was a greater likelihood of garnering support for this
work.
As geneticists the late 1990’s and early 2000’s
was an exciting time where the major accomplish-
ments centered almost completely on monogenic
forms of disease. It is hard to convey the urgency and
excitement of gene identification during this time.
Finding a new genetic cause of disease was a major
undertaking, requiring collaboration between geneti-
cists and clinicians; the latter had sometimes spent
decades tracking down and characterizing rare fam-
ilies, and the former invested enormous amounts of
time, effort, and money on a somewhat unpredictable
process. However, the payoff was huge, the promise
of mutations were that they could provide a molec-
ular start with which to piece together the disease,
they were a tangible, early, and inarguable compo-
nent in the disease process. The publication of a
novel cause of disease was met with great interest
and these papers were high-profile, well-cited, and
often paradigm altering. A particularly compelling
aspect of this search was that it truly represented the
completion of a puzzle; finding a mutation and know-
ing that this is the cause of disease provides instant
gratification - at that instant you are the only person
in the World to know the solution to a particularly
vexing problem.
Because the rewards were so great, and because
being second to identify a particular genetic lesion
yielded little, gene hunting was an extremely com-
petitive and fast-paced world. This remained true in
the late 1990’s through to 2005. In thinking back over
the sheer scale of work and effort that we and oth-
ers placed in this area, it is perhaps surprising that
only a small number of genes were identified for
PD during this time; however, the influence of these
findings was great. The identification of mutations
in genes encoding parkin, dj1, pink1 and lrrk2 in
addition to the identification of gene dosage muta-
tion of -synuclein represented major advances that
provided insight into the genetic basis of disease
and tools with which to understand the biology of
that influence [2–7]. How close these races to new
mutations could get is illustrated by the fact that
the two papers identifying LRRK2 as a PD gene
appeared back to back in the same issue of “Neuron”
[5, 6].
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IN RISK, LITTLE REWARD
While the main pay dirt for geneticists during
this period was the cloning of monogenic forms
of disease, there was also a great deal of fool’s
gold mined by our attempts to identify common
genetic variants that influence disease risk. APOE
in Alzheimer’s disease was the example that many
of us strove to replicate [8]; however the strength
and frequency of this risk allele quickly proved to
be the exception rather than the rule (and indeed
this was not discovered through candidate analysis
but really by family based linkage) [9]. The ease in
which candidate gene association studies could be
executed meant that anyone with a thermal cycler
and a hundred samples could perform a study that
would be published. This lead to an overabundance
of reported associations, which almost all proved to
be false positives. With hindsight the view that the
right gene and the right variant could be selected
based on a perception of biological understanding
was a little self delusional - and it is therefore not
surprising that this was a largely fruitless area of
research.
Although it has been argued that the exceptions
to this folly were SNCA and MAPT [10, 11] these
genes were really nominated as candidates for PD
based on existing genetic or pathologic evidence,
the former of which was based on unbiased genetic
evidence (ie monogenic gene cloning) the latter
from characterization of a major deposited species
in neurodegenerative disease [12–15]. The one true
exception to this is the finding that heterozygous GBA
mutations predispose to PD. This observation was
made through the keen clinical observation that the
parents and grandparents of children with Gaucher’s
disease had an increased incidence of PD (odds ration
of ∼4) [16, 17]. While this idea took time to become
proven and accepted (perhaps we were gunshy from
the previous 10 years of failed associations), it turned
out to be a critical observation. First, of course,
because, it focussed attention on the lysosome and
other lysosomal genes have subsequently been iden-
tified as risk loci for the disease, and second because
it suggested that other heterozygous loss of func-
tion mutations could predispose to late onset disease.
A very similar example of this being TREM2 muta-
tions, which when homozygous cause a young-onset
disorder with a neurological component and when
heterozygous increase risk for Alzheimer’s disease
[18–21].
SECOND GENERATION GENETICS
The most successful approaches in genetics have
centered on an unbiased assessment of variability -
ie genome wide and with good enough coverage to
identify or tag a variant of interest. This is, in essence,
why linkage worked so well - recombinations are
distant enough within families that the heredity of
individual chunks of chromosomes could be easily
traced with only a few hundred sentinel markers. This
type of approach is analogous to rotating through
objective lenses on a microscope, using the positional
information from the current view to zoom in on a
smaller scale area of interest. Conversely the candi-
date approach is more like throwing a slide on, going
straight the highest magnification and hoping to be in
the right place and in focus.
While linkage panels were powerful enough to
detect regions of interest in families, where recom-
binations are few and shared segments are large,
they did not possess sufficient resolution to detect
regions that were identical and shared between dis-
tantly related individuals in a population, particularly
on a genome wide scale. Unbiased detection of com-
mon risk loci, which were generally of small effect
and by definition were ‘old’ alleles therefore required
a very dense assay of genetic variability that could be
performed in a large number of individuals. The intro-
duction of single nucleotide polymorphism (SNP)
chips met this need. Our laboratories were some
of the first to use these methods and it is hard to
overstate the excitement within our groups at per-
forming these experiments and seeing the data. We
were enthusiastic participants in a transition that took
a good lab from a space where they could generate
a few thousand genotypes a day, to one where they
could generate millions. This was a true revolution in
our capabilities, reminiscent of moving from south-
ern blot to PCR amplification. It was certainly one
where we recognized the excitement - with one of
our laboratories working in shifts to ensure data pro-
duction 24 hours a day 7 days a week over a period
of 6 months (even loading chips for scanning on
xmas day).
PD was one of the first diseases to be investigated
using this method, with the second published genome
wide association (GWA) study and the first publicly
available GWA data in a disease [22, 23]. Both of
these studies were unsuccessful in individually iden-
tifying risk variants for PD; however, both laid the
foundation for future work through providing existing
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data and by showing empirically that larger numbers
(and thus collaboration) was needed.
SECOND GENERATION GENETICISTS
With changing methods came a requirement in
a change in the way in which geneticists oper-
ated. The methods were, at first, unproven and
extremely expensive. Array based genotyping initial
cost ∼$1000 a sample and after genotyping a few
hundred cases and controls an individual investigator
was left with a large amount of data, a fairly rudi-
mentary idea about how to analyze it, and a lot of
hope. In the early GWA studies it became quickly
clear that a few hundred or a thousand samples was
simply not enough to see unequivocal association -
and even with an initial genome wide significant sig-
nal, a large amount of replication was required. Thus,
those of us in this area found ourselves experiencing
the 7 stages of high-content genetics grief:
1. Shock - “I can’t believe there’s nothing new to
see”
2. Denial - “there must be something new to see,
we should reanalyze the data”
3. Bargaining - “if you reanalyze the data for me
I’ll give you authorship”
4. Guilt - “all that work and nothing to show for
it”
5. Anger - “I knew I should have worked on single
gene disorders”
6. Depression - “I bet my competitor has found
something and it’s under review somewhere
awesome”
7. Acceptance/hope - “I’m going to have to col-
laborate with someone to increase my n, then
we’ll definitely find something”
On the plus side, geneticists as a group moved
through the grieving process quite quickly. Within
a year or two of the original individual GWA efforts
collaborations were being formed and meta-analyses
executed that indeed identified new genetic loci
for disease [24, 25]. These collaborative groups
formed the basis of large international consortia that
now serve as discovery engines and large reference
datasets in PD genetics. Thus, while we have not
entirely gotten rid of the seven stages, they are cer-
tainly truncated and in large part can be efficiently
dispatched.
Thus, hand in hand with the maturing approach
there has been a remarkable change in culture, from
secretive and isolated single lab approaches, towards
open science, data sharing and collaboration to a
degree that was inconceivable 20 years ago. Inno-
vative models of data acquisition, for example by
direct to consumer genetics companies, are success-
fully used to leverage academic efforts and the use of
cloud based infrastructure is making the sharing and
democratic distribution of massive scale data a reality.
Such an evolution has been a critical step in the forma-
tion of groups that aim to take advantage of the second
generation genetics tools of whole exome sequencing
(WES) and whole genome sequencing (WGS).
The early success of WGS and WES approaches
has been in the area of identifying the cause of
highly penetrant monogenic PD [26–28]. Certainly
these approaches afford a more complete and much
more rapid detection of the genetic causes of rare
familial forms of disease. The expansion of these
efforts into more population based approaches is
underway [29]. These data are easily shared across
sites, particularly using cloud-based infrastructure.
Such sharing not only increases the power to detect
genetic variants of interest but also serves to produce
a reference PD dataset that the field as a whole can
use.
To be clear: a continuation and expansion of data
sharing and collaborations is needed to face the
challenges ahead and to move towards cures. We
still know only a fraction of the total heritability of
PD, some of it presumably still hidden in the huge
number of rare coding variants that are found by
whole exome sequencing. These data will be fully
interpretable only when much larger cohorts are avail-
able that allow us to look at genetic variability at
much higher resolution than to date. And then, the
non-coding regions of the genome, the complexi-
ties of gene-gene and gene-environment interactions
will still prove a considerable but worthwhile
challenge.
RELATIONSHIP STATUS: “IT’S
COMPLICATED”
It should not have been a surprise that the bio-
logical interpretation and understanding of complex
genetic risk factors would in turn be complicated;
however the extent of the challenge that such a prob-
lem holds was perhaps unanticipated. The complexity
of going from (usually) non-coding SNP associa-
tions in GWAs to a mechanistic understanding of
that association is a difficult and multi-dimensional
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problem. Sometimes the gene underlying the asso-
ciation is almost certain (for example, SNPs in both
the SNCA and LRRK2 locus show association with
PD), but even there the effect of the risk haplotype is
not immediately obvious. With SNCA, the association
seems to reflect genetic variability in SNCA expres-
sion, which makes sense in terms of the pathogenic
effect of gene duplications, but the precise mech-
anism of expression control remains unclear. With
LRRK2, again, expression control is likely to be
involved but this has been difficult to dissect and the
effect may in fact be complex and on LRRK2 splicing.
With other loci, the locus dissection is more complex
still, with it often being unclear as to which gene at
the locus underlies the relationship to the disease.
Increasingly, simple genetic analysis to prove gene
associations at a locus, need to be complemented by
whole genome expression studies and bioinformatic
analyses designed to understand whether any partic-
ular gene fits into pathogenic pathways. Thus, data
from many sources need to be integrated: genetic
data (SNP associations, plus the occurrence of rare
high risk variants), gene expression studies (does the
risk SNP correlate with increases or decreases in
expression), protein studies (is the protein a bind-
ing partner of a known PD gene), function studies
(does the protein fit into a pathway already implicated
in disease). Because these data are from different
fields of investigation it remains a challenge to inte-
grate them and have a consistent and reliable view
of the disease mechanism as mediated at any locus.
The challenge of integrating diverse datasets is one
that complex genetics faces across diseases. During
the resolution of these challenges, undoubtedly, mis-
takes will be made, but as more loci are dissected
it should make dissection of subsequent loci easier
just as a jigsaw puzzle gets easier the more pieces are
filled.
WRONG PLACE, WRONG TIME, WRONG
PEOPLE
Much (perhaps all!) of the work we describe above
is aimed at understanding the chain of events that rep-
resent the disease process at the molecular, cellular,
and systems level, with an eye toward developing an
etiologic based intervention. In thinking about why
we have thus far been unsuccessful in introducing
a PD modifying therapy into the clinic it is perhaps
most obvious that we may have been looking in the
wrong place i.e. our understanding about the molec-
ular processes is so imperfect that we do not know
enough to identify a good, clean therapeutic target.
This has almost certainly been the case; however it
is a case that will and already is changing. Thera-
peutics aimed at modifying and effecting Lrrk2 or
alpha-synuclein are etiologically sensible and ratio-
nal and there can be little doubt that more rational
drug design against etiologic targets will be forthcom-
ing; however, unfortunately, even effective therapies
against the right target can fail - if they are applied
at the wrong time or in the wrong subjects. These
two hypothetical barriers to success are predicated
on the ideas that there is likely a critical mass that the
disease process reaches after which it is difficult to
halt the insidious progression, current trials may be
too late in the disease process, being applied at the
wrong time; additionally it may be that there is more
than one etiologic subtype of PD, this is the heart of
the precision medicine movement and it would sug-
gest that certain etiologic-based therapies will only
be successful in patients matched to those therapies
- current trials, which have test PD as a whole, may
have been executed in the wrong people.
Identifying the right patients at the right time is
a considerable challenge - and one that needs to be
met in parallel to understanding the etiology of dis-
ease if we are to maximize our likelihood of success
in trials. This, in our opinion, is a need that must be
met, and one that genetics has a large part to play
in. We envision that our fields approach to identify-
ing risk factors and causes of disease will be adapted
to understand an individual’s risk for disease, when
they are likely to show clinical signs, and to determine
whether there are indeed distinct etiologic subtypes
of PD. Some of this work is already ongoing, with
success in the use of clinically ignorant factors to
predict disease status and to identify PD mimic pre-
sentations [30]. Much more needs to be done in this
regard; clearly genetics alone will not suffice in this
regard and our view is that the greatest likelihood
of success in predicting and subtyping disease will
come through multimodal data, including genetics,
biomarkers, and longitudinal data. In the context of
discovery, our efforts will use genetic tools identi-
cal to those described above but will require cohorts
with much deeper phenotypic and biologic data - a
considerable challenge but one that is beginning to
be met. We predict that the integration of these data,
along with data from basic research, will be the most
efficient path to resolving the challenges of selecting
the right target, for the right patient, and modulating
it at the right time.
S92 A.B. Singleton et al. / The Birth of the Modern Era of Parkinson’s Disease Genetics
A NEW BRAVE NEW WORLD
The remarkable progress of the last 20 years has
opened our eyes to the enormous ocean of unknowns
that lies before us. As a field we have certainly come
a long way, admittedly we’ve strayed off the correct
course occasionally but we are most assuredly closer
to our destination that we were 20 years ago. In many
ways genetics has been the engine that has pushed us
along on our voyage to understand and treat PD, we
know now, more than ever that genetics is a central
component to every case of PD and one for which we
have the tools at hand to understand. So with this in
mind we might be tempted to finish with some more
illustrative hyperbole - “if you’re not working with
genetics, you’re not working on Parkinson’s disease”.
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